surmount-1 trial tirzepatide weight loss nondiabetic non-diabetic Tirzepatide for Obesity: Highlights from the SURMOUNT-1 Tirzepatide maintains weight loss in

GLP-1s support weight loss by: Delaying gastric emptying, which helps you feel fuller for longer after meals Regulating blood sugar, which can support steady energy and fewer cravings Reducing appetite and food noise by acting on hunger-regulating areas of the brain While Ozempic, Wegovy, Foundayo, and Zepbound all fall under the GLP-1 umbrella, Zepbound is unique in that it also targets another hormone called GIP (glucose-dependent insulinotropic polypeptide)

Acute kidney injury has been reported, typically in the context of severe dehydration from gastrointestinal side effects

The available doses are 2.5 mg, 5 mg, 7.5 mg, 10 mg, 12.5 mg, and 15 mg

Hypersensitivity Reactions In a pool of Study 1 and 2, immediate hypersensitivity reactions (within one day after drug administration) occurred in 2.1% of ZEPBOUND-treated patients compared to 0.4% of placebo-treated patients, while non-immediate hypersensitivity reactions occurred in 3.5% of ZEPBOUND-treated patients compared to 2.7% of placebo-treated patients

The SURMOUNT-1 clinical trial showed that participants on 15 mg of tirzepatide lost an average of 22.5% of their body weight over 72 weeks

503A Pharmacies and 503B Outsourcing Facilities